ライフサイエンスコーパス: drug level

1 ificantly less likely to be tested for serum drug level.

2 were also less likely to be tested for serum drug level.

3 r therapeutic drug monitoring to control the drug level.

4 retina was used as a measure of the systemic drug levels.

5 reat to transplant recipients and may affect drug levels.

6 e more rapid dissolution and higher vitreous drug levels.

7 esponse, serving as drug targets and setting drug levels.

8 utilization was also impaired at comparable drug levels.

9 ide nano- and microparticles sustain retinal drug levels.

10 on correlated highly with steady-state brain drug levels.

11 s no significant effect of IVM on DEC or ALB drug levels.

12 cation relative to sex significantly impacts drug levels.

13 antigenemia, adverse events (AEs), and serum drug levels.

14 cing, only 1 of which had low but detectable drug levels.

15 nt are underlying disease and subtherapeutic drug levels.

16 fects with respect to quantification of free drug levels.

17 e infant was reported to develop therapeutic drug levels.

18 sed over time and correlated with the plasma drug levels.

19 e less sensitive and may be normal at trough drug levels.

20 ssociated with poor adherence and low plasma drug levels.

21 F IVRs generated reproducible and protective drug levels.

22 cess more robustly than constant, maintained drug levels.

23 ip between the kappa K(i) and the free brain drug levels.

24 to body weight, equalizing blood and tissue drug levels.

25 cyclosporine implant produced lacrimal gland drug levels 1 to 2 log units higher than those reported

26 This change in drug levels (15% reduction) was made in an attempt to re

27 lated from Donor cells contained appreciable drug levels (2-7pmole/10(6) cells after 24h treatment wi

28 a by day 28 in the CQ arm were noted to have drug levels above 100 ng/ml.

29 heoretical advantage of maintaining constant drug levels above a threshold known from preclinical dat

30 . in vivo Abeta42 lowering in mice occurs at drug levels achievable in humans, and (d). there is a si

31 s observed in U87MG gliomas, consistent with drug levels achieved.

32 atient's immunosuppressive therapy; however, drug levels alone may not reflect the patient's immune s

33 al firing pattern closely mirrors changes in drug level and dopamine overflow observed by previous re

34 by a lack of consistent correlation between drug level and enzyme activity, particularly with chroni

35 In patients with recurrent parasitemia, drug level and genotyping using microsatellite markers w

36 piperazine substituent allowed for excellent drug levels and a long duration of action in the central

37 We found no correlation between trough drug levels and active TGFbeta1 levels in serum of eithe

38 substrate drugs may be at risk of increased drug levels and associated toxicity.

39 armacokinetic data confirmed that the plasma drug levels and clearance rates were similar for patient

40 More information on the relationship between drug levels and clinical outcomes is needed.

41 ction, confound the association between NOAC drug levels and clinical outcomes.

42 NP-470 schedules that produce more prolonged drug levels and clinical trial end points other than obj

43 onse is measured by monitoring pharmacologic drug levels and clinical/pathologic evaluation of graft

44 nalyzed in order to calculate average infant drug levels and determine what factors influence plasma

45 boratory studies, imaging, and monitoring of drug levels and lung function.

46 r (R(2) = 0.89 to 1.00) over a wide range of drug levels and may be used for drug quantification.

47 nding of the role played by heterogeneity in drug levels and pathogen transport is crucial for attemp

48 o, OSU-T315 attains pharmacologically active drug levels and significantly prolongs survival in the T

49 Skin rash also correlated with drug levels and tended to decrease in severity over time

50 time that tumor cells are exposed to maximum drug levels and the drug penetration distance, compared

51 hy/tandem mass spectrometry of intracellular drug levels, and biochemical TKI dissociation studies.

52 , discusses methods to measure and interpret drug levels, and critically assesses the role of routine

53 an be accomplished without increased risk if drug levels are adequately monitored.

54 Increasing preoperative serum anti-TNFalpha drug levels are associated with adverse postoperative ou

55 cal drug delivery; however, sustained tissue drug levels are difficult to achieve with these techniqu

56 use of previous demonstrations that systemic drug levels are effective in preventing SIV infection.

57 lism, and limited clinical data suggest that drug levels are elevated.

58 e, methods to monitor sufficient circulating drug levels are essential.

59 The lower renal drug levels are in keeping with the profound difference

60 rally thought that high systemic and mucosal drug levels are sufficient for protection.

61 ereas glucokinase activity was unaffected at drug levels as high as 1 mmol/l.

62 the clinic to provide sustained therapeutic drug levels at a target site, and thereby reducing the f

63 BAT dosing resulted in drug levels at least as great as those in the absence of

64 s are overall antifungal use, subtherapeutic drug levels at sites of infection/colonization, drug seq

65 s, which yielded negligible tumor and plasma drug levels at the time of treatment with light.

66 dent fashion, with large increases in marrow drug levels beginning at 600 mg bid and with sustained l

67 id suspension injection, with retina-choroid drug levels being higher beginning at 0.25 hour.

68 on reduces dramatically systemic circulating drug levels but leads to significantly higher tissue dru

69 lines were higher than clinically achievable drug levels by 1-37 times for melphalan, 1-9 times for c

70 Subtherapeutic drug levels can be caused by poor adherence to the drug

71 ecifically to the heart, wherein therapeutic drug levels can be maintained over time, is highly desir

72 in the highly compartmentalized human body, drug levels can vary substantially between different org

73 Drug level changes appeared to be partially tumor depend

74 was detected in the tumor regions with high drug levels compared to the tumor regions with low drug

75 een whether preoperative serum anti-TNFalpha drug levels correlate with postoperative morbidity.

76 60 hours into the DX-9065a infusion, plasma drug levels correlated strongly with anti-factor Xa acti

77 r diclofenac sodium salt solution injection, drug levels declined rapidly with no drug levels detecta

78 ection, drug levels declined rapidly with no drug levels detectable after 24 hours in the vitreous hu

79 nature and extent of changes in circulating drug levels due to the presense of food, and their possi

80 ining anemic HCV-infected patients on target drug levels during combination therapy.

81 X sustained aqueous humor and vitreous humor drug levels during the 24-hour study, with a t(1/2) of 9

82 Approximately half achieved protective drug levels during the monthly visits, but adherence dec

83 Detectable serum drug levels equivalent to effective in vitro drug levels

84 traumatic brain injury leading to increased drug levels for an extended period of time after cooling

85 aded nanoparticles provided sustained ocular drug levels for at least 7 days after subconjunctival ad

86 te rapid viremia suppression and therapeutic drug levels; for 10 months, this virus remained R5 tropi

87 Although metformin is renally cleared, drug levels generally remain within the therapeutic rang

88 s drawn at baseline, 4 and 8 weeks for blood drug levels, genome-wide single nucleotide polymorphism

89 SAR 1118 ophthalmic drops delivered retinal drug levels greater than 1 muM in less than 30 minutes a

90 To maintain serum drug levels, however, 21% higher doses of the extended-r

91 anism to account for variability in systemic drug levels; however, declining systemic sorafenib level

92 of a drug is a function of the intracellular drug level in a critical compartment.

93 Information is lacking on the optimal drug level in particular patient groups (eg, elderly, th

94 Plasma drug levels in 26 individuals indicated PrEP use during

95 ations by clinical assays despite detectable drug levels in 8 participants.

96 didates needs to move beyond measurements of drug levels in blood, whole lungs, or alveolar epithelia

97 and determine what factors influence plasma drug levels in breast-feeding infants of mothers treated

98 These results were obtained despite drug levels in cerebrospinal fluid (CSF) that predict cl

99 d there is a tremendous variability in serum drug levels in children.

100 human skin and HPLC was used to analyze the drug levels in different skin layers.

101 s and their effect on adherence, assessed by drug levels in dried blood spots tested monthly for the

102 iously described isoxazoles, yielding higher drug levels in human cancer cells and xenografts.

103 monstrated 4.8-, 15.7-, and 2.1-fold greater drug levels in lung, bronchoalveolar lavage fluid (BAL),

104 347-treated mice readily achieve therapeutic drug levels in peripheral blood.

105 l pharmacokinetic studies in mice, comparing drug levels in spleen to plasma, we selected compounds t

106 ad and that one compound achieved measurable drug levels in the brain.

107 s that impede the achievement of appropriate drug levels in the central nervous system.

108 due to their inability to achieve sufficient drug levels in the CNS.

109 ulature is further suggested by the elevated drug levels in the coronary sinus effluent.

110 approach to achieving sustained, therapeutic drug levels in the eye.

111 ma and tissue stability to achieve increased drug levels in the liver.

112 ing doses of rifampicin resulted in elevated drug levels in the livers of mdr1a (-/-) mice compared w

113 ct correlation between the pore size and the drug levels in the living eye vitreous was confirmed.

114 ith AMB-NIV resulted in significantly higher drug levels in the lungs and skin (p<0.05) compared to s

115 e correlation of clinical effects with brain drug levels in the paroxetine group suggests that relati

116 reast cancer (200 mg/d) achieved only modest drug levels in the prostate and is unlikely to be effect

117 sustained in vitro drug release and in vivo drug levels in the retina for 60 days.

118 ivally to one eye of Sprague-Dawley rats and drug levels in the retina, vitreous, lens, and cornea of

119 Higher detectable drug levels in the retina-choroid suggest rapid settling

120 seizure disorder, with stable anticonvulsant drug levels in the upper half of the therapeutic range,

121 ose of diclofenac sodium solution to sustain drug levels in the vitreous beyond 11 days.

122 Whole-brain drug levels in this group were compared to similarly acq

123 When drug levels in tumors relative to plasma were examined,

124 Drug levels in various ocular tissues were analyzed by l

125 Comparisons among reported serum drug levels indicate that new fluoroquinolones are the l

126 They regulate systemic and cellular drug levels influencing efficacy as well as toxicities.

127 t of the mechanism that transduces declining drug levels into increased drug-related appetitive behav

128 icity or systemic side effects with very low drug levels measured in the aqueous, vitreous, and serum

129 Drug levels measured over the same time course as that u

130 novo sirolimus requires careful therapeutic drug level monitoring, especially the first 6 months pos

131 Drug levels of 17-AAG were determined by high-performanc

132 Data suggest that equivalent plasma drug levels of acyclovir can be achieved after administr

133 studies that reported a relationship between drug levels of dabigatran, rivaroxaban, and apixaban and

134 itumor necrosis factor-alpha (anti-TNFalpha) drug levels on 30-day postoperative morbidity in inflamm

135 ated short IV infusion schedule, daily serum drug levels only briefly exceeded concentrations necessa

136 Subgroup analyses indicate that plasma drug levels or anticoagulant activity of the NOACs predi

137 Drug levels or doses were recorded during the 3 months b

138 mates failed to substantially elevate plasma drug levels or to reduce the development of grade IV CNV

139 er than severe injury, fail to examine brain drug levels or treatment optimization, and do not use an

140 lar fluid samples were used to monitor daily drug levels over 7 days, while clinical responses were a

141 evels compared to the tumor regions with low drug levels (p < 0.05).

142 , and lesions in the presence of therapeutic drug levels (P=.11) were more likely to occur with CsA t

143 n procedures resulting in repeatedly spiking drug levels produce more robust increases in Pmax than p

144 s levels significantly correlated with serum drug levels, providing further evidence for the efficacy

145 hallenge assay measuring plasma nitrates and drug levels, rapidly led to the identification of compou

146 The portal-to-systemic drug level ratio ranged from 0.95 to 2.71 for sirolimus

147 Drug levels reached 6 mug/10(6) cells in human monocyte-

148 possibly methotrexate can increase anti-TNF drug levels, reduce the risk of antidrug antibodies, and

149 of the neurophysiological mechanism by which drug level regulates drug-taking behavior during an ongo

150 significant age effects on brain fluoxetine drug levels remained after adjustment for dose/mass.

151 lerance was sufficiently short that the high drug levels required might be expected to be tolerated c

152 and EPSP slope by 58+/-7% and 31+/-6% of pre-drug levels, respectively.

153 Low drug levels resulting from oral GCV therapy may predispo

154 e or in combination with AZT or D4T, even at drug levels severalfold higher than those used in the vi

155 ot inhibit platelet thromboxane B2 at plasma drug levels similar to those obtained in early clinical

156 1 X d-1) in the study animals yielded plasma drug levels sufficient either to chronically block or, f

157 sorder diagnoses did not receive therapeutic drug level testing during the 12-month study period.

158 e utilization were related to rates of serum drug level testing.

159 1 and 7 days after viral exposure, elicited drug levels that paralleled the human median effective c

160 Cells accumulated intracellular drug levels that were at least 8-fold higher than extrac

161 At intermediate drug levels the spectrum narrowed to F317V and T315I for

162 Intravitreal drug levels, the amount of drug remaining in explanted d

163 were observed at or near clinically relevant drug levels, they preceded lethal injury, and they corre

164 acts as capacitive space for drug and shifts drug levels to decrease tissue uptake 2-fold.

165 is the main determinant of immunosuppressive drug level variability.

166 Plasma drug levels varied considerably between subjects and dec

167 nto the peritoneal cavity, enabling elevated drug levels versus intravenous (i.v.) injection.

168 sinophilia above baseline levels occurred as drug levels waned.

169 ably self-administer cocaine, the cumulative drug level was calculated during sessions in which cocai

170 The vitreous drug level was then measured at different time points.

171 Maintenance of therapeutic drug levels was associated with favorable results.

172 etween 2002 and 2003, the variation of serum drug levels was studied as a potential objective tool to

173 Patients who did receive tests for serum drug level were likely to receive the other recommended

174 drug levels equivalent to effective in vitro drug levels were achieved at the 20-, 30-, and 40-microg

175 eatment was discontinued once therapeutic CI drug levels were achieved.

176 Steady-state drug levels were associated with a 5-HT uptake inhibitio

177 The tumor regions containing high drug levels were associated with a higher degree of vasc

178 dolescence, underweight, and/or undetectable drug levels were at higher risk of failing second-line A

179 Serum drug levels were evaluated in a subset of patients.

180 Plasma drug levels were followed and outcome measures included

181 Drug levels were found to decline significantly over tim

182 Throughout the assessed time course, drug levels were higher in the vitreous.

183 Plasma drug levels were linear with dose.

184 However, sustained, high drug levels were observed in both the vitreous humor and

185 ficant synergy was observed at physiological drug levels when PYR/SDX acted on purified DHFR, whether

186 iation (aHR, 2.8; P = .03), and undetectable drug levels within 6 months following second-line initia

187 gh it is possible to accurately measure NOAC drug levels, within-patient variability complicates inte

188 and the resultant achievement of high plasma drug levels without associated nausea or emesis.